Psilocybin-Research.com Research. Clarity. Progress.
Preparing publication tracker
Psilocybin-Research.com Research. Clarity. Progress.

Psilocybin Research Publication Tracker

Search, analyze, export, and monitor psilocybin and psilocin literature across peer-reviewed papers, preprints, reviews, protocols, and clinical trials.

Database up to date Last update: Jul 3, 2026 01:22 UTC
Database evidence 3,975 indexed records
Indexed records 3,975 SQLite literature index
Published 3,210 Peer-reviewed / formal records
Preprints 478 Marked as not peer reviewed
Clinical trials 287 ClinicalTrials.gov records
Source coverage 8 active sources
Source Count Share Status
Europe PMC 2,554 64.3% Active
PubMed 302 7.6% Active
ClinicalTrials.gov 287 7.2% Active
OpenAlex 283 7.1% Active
PsyArXiv 216 5.4% Active
Crossref 157 3.9% Active
bioRxiv 142 3.6% Active
Publication timeline 3,072 dated records
3,072 records since 2020
Annual records Cumulative line
3,975Total Publications
3,834Psilocybin Records
553Psilocin Records
Search Matches
388Journals
66Research Topics
Current display No search or filter specified Showing the latest indexed records until a keyword search is submitted.
Page 14 of 199

Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption.

Mystical experiences are characterized by a profound sense of interconnectedness and transcendence of ordinary reality. These experiences can facilitate feelings of connectedness with oneself and others and have been documented as leading to significant positive changes in thoughts, emotions, and behavior. The purpose of the present study was to evaluate the...

Unknown journal 2026-04-29 Briggs D, Sease TB, Menou R, Perkins DR.
Europe PMC Published psilocybin Emotional ProcessingMystical ExperiencePsychological Flexibility Other

Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)

Background: Terminally ill patients often experience significant psychosocial distress having depressed mood, death anxiety, pain, and an overall poor quality of life. Recent evidence from pilot studies suggests that serotonergic hallucinogens including lysergic acid diethylamide (LSD) and psilocybin produce significant and sustained reductions of depressive...

ClinicalTrials.gov 2026-04-28 University Hospital, Basel, Switzerland
ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyEnd-of-Life DistressChronic PainClinical Trial Clinical Trial Palliative CarePain

A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back Pain

This study evaluates whether psilocybin therapy helps patients cope with chronic low back pain more effectively. Patients may be recruited at Stanford and University of California San Francisco (UCSF), study procedures will occur at UCSF. Each participant will receive a dose of psilocybin with possibly one or more other drugs. Participants will undergo two p...

ClinicalTrials.gov 2026-04-28 Joshua Woolley, MD, PhD
ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionChronic PainEmotional Processing Clinical Trial Chronic Low-back PainPsilocybin therapy with Zolpidem and Modafinil

The Ecstasy of Gold in Neurodiversity: Focus on the Use of Psychedelics in Autism Spectrum Disorder

Psychedelic drugs are serotonergic hallucinogens that can be divided into two types: naturally occurring (psilocybin, psilocin, and N,N-dimethyltryptamine) and synthetic (LSD, MDMA, 2,5-dimethoxy-4-iodoamphetamine, and ketamine). Psychedelics generally work on 5-hydroxytryptamine receptors and might be useful in cognitive enhancement, brain connectivity, neu...

Preprints.org 2026-04-28 Marini S, De Berardis D.
Europe PMC PREPRINT (not peer reviewed) psilocybinpsilocin NeuroplasticityReceptor PharmacologySafety Other

A128-Channel Wireless Wearable Myolink (W2 Myolink): Functional Characteristics and Multidisciplinary Experiments

Abstract This paper presents Wireless Wearable Myolink (W2 Myolink), a high-density, battery-powered system for wireless acquisition of surface electromyography(EMG) signals, and demonstrates its practicality across diverse experimentalparadigms. The device features a compact form factor (110x70x35 mm), low weight(160 g), and continuous operation for up to 6...

Research Square 2026-04-27 Zajaczkowski M, Koutsoftidis S, Sheeraz M, Barsakcioglu DY, Jia T, McGeady CA, Kundu A, Pizzi M, Tatti F, Bashford J, Bhavesh P, Farina D, Drakakis E.
Europe PMC PREPRINT (not peer reviewed) psilocybin Brain ImagingDrug Interactions Other

Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review.

IntroductionThis article presents a narrative review of psilocybin-assisted psychotherapy as a promising intervention for addressing anxiety, depression and psycho-existential distress in patients with advanced cancer. This group of disorders, often resistant to conventional treatments, significantly impacts patients' quality of life and autonomy, as well as...

Unknown journal 2026-04-27 Magnani L, Ghirotto L, Fesce F, Re T, Tanzi S, Amerio A, Costanza A.
Europe PMC Published psilocybin DepressionAnxietyEnd-of-Life DistressChronic PainReview ArticleCancer PatientsInflammation Review Article HumansNeoplasms

The Harmonious Dance: A Narrative Review on Psychedelics and Music in Therapeutic Settings.

The integration of psychedelics and music in therapeutic settings is gaining recognition for its potential to enhance mental health outcomes. This review synthesizes current evidence on the neurobiological mechanisms underlying this synergy, focusing on receptor-level pathways (e.g., 5-HT2A receptor agonism, BDNF-TrkB signaling) and neural circuit dynamics (...

Current neuropharmacology 2026-04-27 Wang H, Li X, Yu F, Wang X
PubMed Published psilocybin DepressionAnxietyPTSDAddictionNeuroplasticityMechanism of ActionReceptor PharmacologyDefault Mode NetworkEmotional ProcessingReview ArticleDrug Interactions Review Article Psychedelicsdefault mode network

Fusing Specialized Surveys of Rare Populations to Larger Surveys for Generalized Inference: Cross-Sectional Survey Study.

BackgroundMainstays of pharmacoepidemiology are large, representative, behavioral surveys, which focus on many drugs with few detailed behaviors. Smaller, targeted studies measure drug-specific patterns but without explicit generalizability assumptions; the evidence generated is narrow.ObjectiveIn this cross-sectional survey study, we outline an estimation f...

Unknown journal 2026-04-26 Rockhill KM, Bemis EA, Schow N, Olsen HA, Beekman K, Fox EJ, Monte AA, Black JC.
Europe PMC Published psilocybin AddictionObservational Study Observational Study HumansHallucinogens

"Large-Scale and Local Functional Connectivity Changes Following Psilocybin Administration in Methamphetamine Use Disorder.

Background and purposeMethamphetamine (MA) use disorder is associated with widespread disruption of large-scale brain networks involved in cognitive control, attention, and salience processing. Resting-state functional MRI (rs-fMRI) provides a means to characterize these alterations; however, little is known about the capacity for functional network reorgani...

Unknown journal 2026-04-23 Chaganti J, Siefried KJ, Vyakaranam VS, Acheson L, Brett J.
Europe PMC Published psilocybin AddictionNeuroplasticityBrain ImagingBiomarkersAging Other

Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia.

Chronic pain states remain challenging to control with current drug therapies. Here, we demonstrate that a single dose of psilocybin produces a sustained anti-nociceptive effect in chronic neuropathic pain models in male and female mice, mediated primarily by 5-HT2A receptors. Critically, psilocybin significantly potentiates the analgesic efficacy of gabapen...

Unknown journal 2026-04-23 Askey T, Allen-Ross D, Luzyanin D, Lasrado R, Gilmour G, Hunt SP, Tamagnini F, Ahmed M, Stephens GJ, Maiarú M.
Europe PMC Published psilocybin Chronic PainReceptor PharmacologyAnimal Study Animal Study AnimalsMice

Methamphetamine-Fentanyl Polysubstance Administration Produces Social Deficits and Corticolimbic Stress-Reward Circuit Adaptations

Abstract Rationale and Objectives: Polysubstance use involving psychostimulants and opioids is increasingly prevalent and associated with elevated overdose risk, relapse vulnerability, and poor treatment outcomes. However, the neurobehavioral consequences of opioid-stimulant use remain poorly understood. We evaluated whether repeated methamphetamine-fentanyl...

Research Square 2026-04-22 Salinsky LM, Fox JL, Diaz KC, Timmons BC, Ferguson SM.
Europe PMC PREPRINT (not peer reviewed) psilocybin AddictionSafety Other

Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects.

Autism Spectrum Disorder (ASD) is characterized by persistent social-communication deficits, cognitive rigidity, and atypical sensory processing. Current pharmacological treatments, including risperidone and aripiprazole, provide only limited symptomatic relief and do not address the underlying neurobiological mechanisms. Converging evidence implicates dysre...

Unknown journal 2026-04-22 Low ZXB.
Europe PMC Published psilocybin NeuroplasticityMechanism of ActionReceptor PharmacologyClinical TrialReview ArticleAnimal StudySafetyInflammationImmune Function Clinical Trial BrainAnimals

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder. The trial will take place with individuals admitted to a residential rehabilitation treatment program. The treatment protocol will consist of 4 preparatory therapy visits, 2 psil...

ClinicalTrials.gov 2026-04-21 Portland VA Research Foundation, Inc
ClinicalTrials.gov CLINICAL TRIAL psilocybin Clinical TrialSafety Clinical Trial Amphetamine-Related DisordersPsilocybin

A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)

One hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation under double-blind conditions to receive a single 25 mg oral dose of psilocybin or a single 100 mg oral dose of niacin. Niacin wil...

ClinicalTrials.gov 2026-04-21 Usona Institute
ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionHealthy VolunteersSafety Clinical Trial Depressive DisorderMajor

Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy

The goal of this pilot clinical trial is to learn whether it is feasible to individually tailor psilocybin-assisted psychotherapy (PAP) for people with treatment-resistant depression (TRD) based on their personal preferences. The study also aims to explore whether two different psychotherapy styles, music-centered and mindfulness-centered, influence how peop...

ClinicalTrials.gov 2026-04-21 Kyle Greenway
ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionWellbeingClinical TrialTreatment-Resistant DepressionSafety Clinical Trial Treatment-Resistant Major Depressive DisorderPsilocybin 25mg

Distinct Modulatory Effects on Affective Biases by Different Serotonergic Psychedelics and MDMA in Male Rats: Possible Implications for Antidepressant Effects

Affective biases are important neuropsychological mechanisms by which emotions modulate cognition, behaviour and the subjective experience of mood. Previous studies have shown that the rapid-acting antidepressant, ketamine, and serotonergic psychedelic, psilocybin, modulate affective biases in a translational rat model. Both treatments differ from convention...

bioRxiv 2026-04-21 Hinchcliffe JK, Bartlett J, Thomas CW, Golden CT, Gilmour G, Bortolotto ZA, Robinson ES.
bioRxiv PREPRINT (not peer reviewed) psilocybin PharmacologyMechanism of ActionReceptor PharmacologyEmotional ProcessingAnimal Study Animal Study

Psilocybin as an alternative to conventional treatments: A systematic review

Introduction. Limitations of conventional treatments for depression and anxiety, particularly in treatment-resistant cases, have driven interest in alternative therapeutic approaches. Psilocybin, a serotonergic agonist with demonstrated effects on neuroplasticity and large-scale brain networks, has emerged as a promising therapeutic option. Materials and met...

Gaceta Médica de Caracas 2026-04-21 Cahuasqui-Mendoza Deivid Antonio
Crossref Published psilocybin DepressionAnxietyNeuroplasticityClinical TrialSystematic ReviewReview ArticleSafety Systematic Review

Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site.

PurposeTo examine the prevalence of lifetime ("ever") cannabis and classic psychedelic use, and their co-use among U.S. adults aged ≥ 50 years with versus without a lifetime history of cancer, and to describe variation by cancer type/site among survivors.MethodsWe analyzed pooled 2015-2019 and 2021-2022 National Survey on Drug Use and Health (NSDUH) data of ...

Unknown journal 2026-04-21 Baral A, Pan Y, Hlaing WM, Garcia-Romeu A, Pinheiro PS, Vidot DC.
Europe PMC Published psilocybin Observational Study Observational Study HumansNeoplasms

Wherefore the Magic? The Evolutionary Role of Psilocybin in Nature.

Research into psychedelic compounds is in resurgence because of the exciting potential for their use in the treatment of psychiatric and mental health disorders. Despite this revival, remarkably little is known about their evolution. One of the most intriguing psychedelic compounds is psilocybin, the compound found in 'magic' mushrooms and used in ritual cer...

Unknown journal 2026-04-21 Matthews Nicholass KJ, Flis I, Hanley ME, Knight ME, Lane SM, Littlejohn G, Thom MDF, Billington RA, Boden R, Cummins R, Green BJ, Griffin C, Jones S, Salmon D, Sleep I, Smirnoff N, Ellis JS.
Europe PMC Published psilocybin Mechanism of ActionReceptor PharmacologyDrug Interactions Other

Live source coverage

3,975 indexed records across 8 active sources.

3,210Published
478Preprints
287Clinical trials
  1. Europe PMC 2,554 records · 64.3%
  2. PubMed 302 records · 7.6%
  3. ClinicalTrials.gov 287 records · 7.2%
  4. OpenAlex 283 records · 7.1%
  5. PsyArXiv 216 records · 5.4%
  6. Crossref 157 records · 3.9%
  7. bioRxiv 142 records · 3.6%
  8. medRxiv 34 records · 0.9%

Counts exclude hidden records and curated false positives. Preprints remain labeled as not peer reviewed in search results and exports.